Press Release: Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
Syros Pharmaceuticals(SYRS.US) Director Sells US$178.37K in Common Stock
Form 144 | Syros Pharmaceuticals(SYRS.US) Director Proposes to Sell 199.27K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 28, $Syros Pharmaceuticals(SYRS.US)$ Director Young Richard A intends to sell 34,837 shares of its common stock on Jun 28, with a total market value of approximately $199.2
TD Cowen Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating
Syros Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating, Maintains Target Price $15
JMP Securities Maintains Syros Pharmaceuticals(SYRS.US) With Buy Rating, Maintains Target Price $12
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 17% Over Last Week
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients With RARA Gene Overexpression
HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
Optimistic Outlook for Syros Pharmaceuticals With Promising Clinical Trials and Regulatory Advancements
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
Earnings Call Summary | Syros Pharmaceuticals(SYRS.US) Q1 2024 Earnings Conference
Buy Rating Affirmed for Syros Pharmaceuticals Amidst Clinical Advancements and Market Readiness
Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript
Express News | Syros Pharmaceuticals Inc: Cash, Cash Equivalents and Marketable Securities as of March 31, 2024, Were $108.3 Mln
Syros Pharmaceuticals 1Q Rev $2.95M >SYRS
Express News | Syros Pharmaceuticals Q1 2024 GAAP EPS $(0.10) Beats $(0.86) Estimate, Cash (Incl Restricted Cash) $85.64M